États-Unis · Bourse & Finance · Morningstar

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

Publié par Morningstar · États-Unis il y a 17 h

NORTH CHICAGO, Ill., Oct. 11, 2026 /PRNewswire/ -- AbbVie today announced the presentation of 22 scientific abstracts from its market-leading inflammatory bowel disease (IBD)…

Lire l'article complet sur Morningstar Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.morningstar.com)

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

À lire aussi

The investor’s guide to TechCrunch Disrupt 2026: Everything you need to know

Starknet coin surges as developer weighs Ethereum split over quantum security

For the first time ever, 10-year bond yields track diesel prices more closely than crude, and Trump’s fuel deal with Putin may be too little too late

Tokenized Stocks Show Real Demand But Remain Volatile and Illiquid, IMF Finds

From BJ’s to Lululemon, retailers are trimming assortments to boost business

Saylor teases Strategy Bitcoin buying after ending September with STRC buybacks

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

Partager

À lire aussi

The investor’s guide to TechCrunch Disrupt 2026: Everything you need to know

Starknet coin surges as developer weighs Ethereum split over quantum security

For the first time ever, 10-year bond yields track diesel prices more closely than crude, and Trump’s fuel deal with Putin may be too little too late

Tokenized Stocks Show Real Demand But Remain Volatile and Illiquid, IMF Finds

From BJ’s to Lululemon, retailers are trimming assortments to boost business

Saylor teases Strategy Bitcoin buying after ending September with STRC buybacks